However, in addition to copper depletion-related anemia and neutropenia, ATN-224 also led to grade 3 fatigue after 14 days of treatment, which was dose-limiting and correlated with the dosage of ATN-224 and the rate of cp reduction.411 A phase II clinical trial on biochemically recurrent prostate cancer patients found that low-dose ATN-224 (30 mg/day) may exhibit biological activity.412 However, the clinical significance of prostate-specific antigen (PSA) dynamics in this population remains uncertain. Here, KLK3 is linked to prostate carcinoma.